ORCHARD THERAPEUTICS NORTH AMERICA

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$2.8M

Filings

Firms Hired

Active Period

2019–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$1,250,000	13	4
2025	$1,400,000	25	6
2024	$190,000	11	4
2023	—	4	1
2022	—	9	2
2021	—	11	3
2020	—	4	1
2019	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ORCHARD THERAPEUTICS NORTH AMERICA	$2,840,000	13
THE MCMANUS GROUP	—	13
S-3 GROUP	—	9
LMH STRATEGIC SOLUTIONS	—	7
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS	—	8
LEAVITT PARTNERS, LLC	—	8
SIMS STRATEGIES, LLC	—	9
CROSSROADS STRATEGIES, LLC	—	5
CORNERSTONE GOVERNMENT AFFAIRS, INC.	—	5
THEGROUP DC, LLC	—	3

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	59
SENATE	59
Health & Human Services, Dept of (HHS)	17
Food & Drug Administration (FDA)	9
Centers For Medicare and Medicaid Services (CMS)	8
Executive Office of the President (EOP)	4
White House Office	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	59
Medicare/Medicaid	Medicare/Medicaid	29
Budget/Appropriations	Budget/Appropriations	22
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	9
Pharmacy	Pharmacy	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2026 · third_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $10,000

Matched citations: H.R. 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2026 · third_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $10,000

Matched citations: S. 752

H.R. 10571119th Congress

Surge to Save Newborns Act

2026 · third_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act

Client expense: $240,000 · Firm income: —

Matched citations: H.R. 10571

H.R. 7871119th Congress

MVP Act

2026 · third_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Client expense: $240,000 · Firm income: —

Matched citations: H.R. 7871

Show 21 more cited filings

S. 1637119th Congress

MVP Act

2026 · third_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Client expense: $240,000 · Firm income: —

Matched citations: S.1637

H.R. 7871119th Congress

MVP Act

2026 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Client expense: $190,000 · Firm income: —

Matched citations: H.R. 7871

S. 1637119th Congress

MVP Act

2026 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Client expense: $190,000 · Firm income: —

Matched citations: S.1637

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2026 · second_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2026 · second_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: S. 752

H.R. 7871119th Congress

MVP Act

2026 · first_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's

Client expense: $470,000 · Firm income: —

Matched citations: H.R. 7871

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2026 · first_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $30,000

Matched citations: H.R. 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2026 · first_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $30,000

Matched citations: S. 752

H.R. 7871119th Congress

MVP Act

2026 · first_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's

Client expense: $350,000 · Firm income: —

Matched citations: H.R. 7871

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

Client expense: $430,000 · Firm income: —

Matched citations: HR 1262

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Client expense: $430,000 · Firm income: —

Matched citations: HR 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Client expense: $430,000 · Firm income: —

Matched citations: S 752

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · second_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

Client expense: $430,000 · Firm income: —

Matched citations: S 932

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · fourth_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262/ S 932 - Give Kids a Chance Act of 2025 HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025 Newborn Screening, including Appropriations

Client expense: $260,000 · Firm income: —

Matched citations: HR 1262

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · fourth_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262/ S 932 - Give Kids a Chance Act of 2025 HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025 Newborn Screening, including Appropriations

Client expense: $260,000 · Firm income: —

Matched citations: HR 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · fourth_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262/ S 932 - Give Kids a Chance Act of 2025 HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025 Newborn Screening, including Appropriations

Client expense: $260,000 · Firm income: —

Matched citations: S 752

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · fourth_quarter · Firm: ORCHARD THERAPEUTICS NORTH AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262/ S 932 - Give Kids a Chance Act of 2025 HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025 Newborn Screening, including Appropriations

Client expense: $260,000 · Firm income: —

Matched citations: S 932

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · fourth_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · fourth_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: S. 752

H.R. 1509119th Congress

Accelerating Kids’ Access to Care Act of 2025

2025 · third_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1509

S. 752119th Congress

Accelerating Kids’ Access to Care Act

2025 · third_quarter · Firm: LEAVITT PARTNERS, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Client expense: — · Firm income: $20,000

Matched citations: S. 752

Source: Senate LDA

ORCHARD THERAPEUTICS NORTH AMERICA — Lobbying Disclosure | Poliscope